The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
Bezawit A. Woldemeskel, Andrew H. Karaba, Caroline C. Garliss, Evan J. Beck, Kristy Wang, Oliver Laeyendecker, Andrea L. Cox, Joel N. Blankson
Abstract
Previous studies have shown that certain vaccines induce suboptimal responses in people living with human immunodeficiency virus (HIV, PLWH). However, responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have not been fully characterized in these patients. Here we show that the BNT162b2 vaccine induces robust immune responses comparable to responses in healthy donors.
Topics & Concepts
MedicineImmune systemImmunologyHuman immunodeficiency virus (HIV)VirologyImmunodeficiencyVirusSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies